Background Indigenous peoples experience substantial mental health and substance use disparities while remaining underserved by conventional healthcare systems. Despite growing evidence for psychedelic-assisted therapies, Indigenous knowledge systems and Indigenous-led models of psychedelic care remain underrepresented. This paper describes the establishment and implementation of the Yaqui...
Psychedelic substances are under investigation in several drug development programs. Controlled clinical trials are providing evidence for safe and effective use of psychedelic therapies for treating mental health conditions. With the anticipated FDA approval of MDMA-assisted therapy for posttraumatic stress disorder in 2023 and psilocybin therapy for depression disorders soon after, now is the...